NVSEF Quote, Financials, Valuation and Earnings

Addex Therapeutics has a net margin of 24.21% compared to Novartis AG's net margin of -2841.85%. Novartis AG's return on equity of 41.89% beat Addex Therapeutics's return on equity of 91.08%.

Novartis AG has a consensus price target of --, signalling downside risk potential of -15.13%. On the other hand Addex Therapeutics has an analysts' consensus of -- which suggests that it could grow by 275.4%. Given that Addex Therapeutics has higher upside potential than Novartis AG, analysts believe Addex Therapeutics is more attractive than Novartis AG.

Novartis AG has a beta of 0.569, which suggesting that the stock is 43.089% less volatile than S&P 500. In comparison Addex Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Novartis AG has a quarterly dividend of $3.74 per share corresponding to a yield of 3.83%. Addex Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novartis AG pays 48.86% of its earnings as a dividend. Addex Therapeutics pays out -- of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.2B, which are larger than Addex Therapeutics quarterly revenues of $62.3K. Novartis AG's net income of $3.2B is higher than Addex Therapeutics's net income of -$1.8M. Notably, Novartis AG's price-to-earnings ratio is 11.47x while Addex Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.02x versus 14.76x for Addex Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

CRISPR Therapeutics AG has a net margin of 24.21% compared to Novartis AG's net margin of --. Novartis AG's return on equity of 41.89% beat CRISPR Therapeutics AG's return on equity of --.

Novartis AG has a consensus price target of --, signalling downside risk potential of -15.13%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.75 which suggests that it could grow by 99.68%. Given that CRISPR Therapeutics AG has higher upside potential than Novartis AG, analysts believe CRISPR Therapeutics AG is more attractive than Novartis AG.

Novartis AG has a beta of 0.569, which suggesting that the stock is 43.089% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.621, suggesting its more volatile than the S&P 500 by 62.069%.

Novartis AG has a quarterly dividend of $3.74 per share corresponding to a yield of 3.83%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novartis AG pays 48.86% of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.2B, which are larger than CRISPR Therapeutics AG quarterly revenues of --. Novartis AG's net income of $3.2B is higher than CRISPR Therapeutics AG's net income of -$85.9M. Notably, Novartis AG's price-to-earnings ratio is 11.47x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.02x versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

NLS Pharmaceutics has a net margin of 24.21% compared to Novartis AG's net margin of --. Novartis AG's return on equity of 41.89% beat NLS Pharmaceutics's return on equity of --.

Novartis AG has a consensus price target of --, signalling downside risk potential of -15.13%. On the other hand NLS Pharmaceutics has an analysts' consensus of -- which suggests that it could grow by 12574.27%. Given that NLS Pharmaceutics has higher upside potential than Novartis AG, analysts believe NLS Pharmaceutics is more attractive than Novartis AG.

Novartis AG has a beta of 0.569, which suggesting that the stock is 43.089% less volatile than S&P 500. In comparison NLS Pharmaceutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Novartis AG has a quarterly dividend of $3.74 per share corresponding to a yield of 3.83%. NLS Pharmaceutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novartis AG pays 48.86% of its earnings as a dividend. NLS Pharmaceutics pays out -- of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.2B, which are larger than NLS Pharmaceutics quarterly revenues of --. Novartis AG's net income of $3.2B is higher than NLS Pharmaceutics's net income of --. Notably, Novartis AG's price-to-earnings ratio is 11.47x while NLS Pharmaceutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.02x versus -- for NLS Pharmaceutics. Usually stocks with elevated PS ratios are considered overvalued.